Medicines and Healthcare products Regulatory Agency

MANUFACTURER'S AUTHORISATION

1: Authorisation Number UK MIA(IMP) 4351

2: Name of authorisation holder PENN PHARMACEUTICAL SERVICES LIMITED

PENN PHARMACEUTICAL SERVICES LIMITED, UNITS 23-24,

3: Address(es) of manufacturing site(s) TAFARNAUBACH INDUSTRIAL ESTATE, TAFARNAUBACH, TREDEGAR,

NP22 3AA, UNITED KINGDOM

PENN PHARMACEUTICAL SERVICES LIMITED, UNITS 23-24,

4: Legally registered address of authorisation holder TAFARNAUBACH INDUSTRIAL ESTATE, TAFARNAUBACH, TREDEGAR,

NP22 3AA, UNITED KINGDOM

5: Scope of authorisation and dosage forms ANNEX 1 and/ or ANNEX 2

6: Legal Basis of authorisation

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI

2004/1031]

7: Name of responsible officer of the competent

authority of the member state granting the

manufacturing authorisation

Confidential

8: Authorisation Date 29/01/2025

9: Annexes attached Annex 1 and/or Annex 2

SCOPE OF AUTHORISATION

Annex 2

Name and address of the site:

PENN PHARMACEUTICAL SERVICES LIMITED, UNITS 23-24, TAFARNAUBACH INDUSTRIAL ESTATE, TAFARNAUBACH, TREDEGAR, NP22 3AA, UNITED KINGDOM

Human Investigational Medicinal Products

Authorised Operations

MANUFACTURING OPERATIONS (according to part 1)

IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)

Part 1 - MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.3] Batch certification

[1.2] Non-sterile investigational medicinal products

[1.2.1] Non-Sterile Products (processing operations for the following dosage forms)

Issue Date: 29 Jan 2025

[1.2.1.1] Capsules, hard shell **Special Requirements** Inclusion of Potent, Toxic Compounds [1.2.1.5] Liquids for external use **Special Requirements** Inclusion of Potent, Toxic Compounds [1.2.1.6] Liquids for internal use **Special Requirements** Inclusion of Potent, Toxic Compounds [1.2.1.11] Semi-solids **Special Requirements** Inclusion of Potent, Toxic Compounds [1.2.1.12] Suppositories **Special Requirements** Inclusion of Potent, Toxic Compounds [1.2.1.13] Tablets Special Requirements Inclusion of Potent, Toxic Compounds [1.2.1.15] Other non-sterile medicinal products Capsules Hard Shell - encapsulation of cytotoxic tablets, Filling of Powders. [1.2.2] Batch certification [1.4] Other investigational medicinal products or manufacturing activitiy [1.4.1] Manufacture of: [1.4.1.1] Herbal products [1.5] Packaging [1.5.1] Primary packaging [1.5.1.1] Capsules, hard shell **Special Requirements** Inclusion of Potent, Toxic Compounds [1.5.1.5] Liquids for external use **Special Requirements** Inclusion of Potent, Toxic Compounds [1.5.1.6] Liquids for internal use **Special Requirements** Inclusion of Potent, Toxic Compounds [1.5.1.11] Semi-solids **Special Requirements** Inclusion of Potent, Toxic Compounds [1.5.1.12] Suppositories **Special Requirements** Inclusion of Potent, Toxic Compounds [1.5.1.13] Tablets **Special Requirements** Inclusion of Potent, Toxic Compounds [1.5.1.15] Other non-sterile medicinal products Filling of powders. Capsule hard shells encapsulation of cytotoxic tablets [1.5.2] Secondary packaging [1.6] Quality control testing

Issue Date: 29 Jan 2025

[1.6.2] Microbiological: non-sterility [1.6.3] Chemical/Physical Part 2 - IMPORTATION OF MEDICINAL PRODUCTS [2.1] Quality control testing of imported medicinal products [2.1.2] Microbiological: non-sterility [2.1.3] Chemical/Physical [2.2] Batch certification of imported medicinal products [2.2.1] Sterile Products [2.2.1.1] Aseptically prepared [2.2.1.2] Terminally sterilised [2.2.2] Non-sterile products [2.2.3] Biological medicinal products [2.2.3.1] Blood products [2.2.3.2] Immunological products [2.2.3.5] Biotechnology products [2.2.3.6] Human or animal extracted products [2.3] Other Importation Activities



Page 3 of 3 Issue Date: 29 Jan 2025

[2.3.1] Site of Physical Importation

[2.3.2] Importation of Intermediate which undergoes further processing